

Amalgamation of quercetin with anastrozole and capecitabine: A novel combination to treat breast and colon cancers – An *in vitro* study

ABSTRACT

Context: Globally, cancer stands as the principle cause of mortality and immediate attention on its treatment options is required. Natural compounds stay at first priority in encountering novel therapeutics without adverse effects.

Aim: The aim of the study is to extract flavonol quercetin from leafy vegetables of *Anethum graveolens* L. and *Raphanus sativus* L. and find out its potential in combination with drugs used for chemotherapy to reduce the adverse effects of drugs.

Settings and Design: Observational study.

Materials and Methods: Column chromatography is used for quercetin extraction and anticancer activity of quercetin + anastrozole and quercetin + capecitabine were determined by (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay (MTT), apoptosis assay, cell cycle analysis, mitochondrial membrane potential, and caspase 3 expression.

Statistical Analysis Used: Cytotoxic assay results were assessed by mean, standard deviation and ANOVA; and results were compared for determining its significance.

Results: The results noted that quercetin at very less concentration (16 and 31 µg/ml on Michigan Cancer Foundation-7 and 43 and 46 µg/ml on COLO 320) in combination with anastrozole and capecitabine was able to control the growth of cells, increase cell death, arrest cell cycle, and induce mitochondrial depolarization and expression of caspase 3.

Conclusions: The natural compound used in the present study is effective in treating breast and colon cancer at minimal concentrations in combination with the drugs. This combinational treatment appears to be reported for the first time in the present study.

KEY WORDS: Anticancer, COLO 320, flavonoid, Michigan Cancer Foundation-7

INTRODUCTION

Cancer, being top ranked, files about 9.6 million deaths a year that triggered the drug investigators to identify novel molecules.^[1] According to 2018 reports of the World Health Organization, the top ranked cancers were breast and colorectal which relies on “one size fits all” approach for treatment. During initial treatment, cancer cells easily gain drug resistance by activation of biological pathways.^[2,3] These combinations were preferred majorly in chemotherapy.^[4] Drugs such as anastrozole is effective in combination with other drugs for treating breast cancer patients after surgery.^[5,6] Capecitabine is opted for off-label indications in colorectal cancer exclusively for monotherapy in advanced or metastatic settings. Its combination with oxaliplatin in the advanced or metastatic settings and

concurrent radiations is used for the neoadjuvant treatment in colorectal cancer.^[7,8] Hence, introduction of unrevealed combinations would be a promising approach to achieve impairments in minimizing side effects coupled with conventional chemotherapy that cracks on quercetin.

Flavonoids are proved anticancer agents, among which quercetin has ability over cell-signaling, pro-apoptotic, antiproliferative, and antioxidant

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

**Mary Shobha
Rani Inala,
Kiranmayee
Pamidimukkala**

Department of Cell
Biology and Molecular
Genetics, Sri Devaraj
Urs Academy of
Higher Education and
Research, Tamaka,
Kolar, Karnataka,
India

For correspondence:

Dr. Kiranmayee
Pamidimukkala,
Department of Cell
Biology and Molecular
Genetics, Sri Devaraj
Urs Academy of
Higher Education and
Research, Tamaka,
Kolar - 563 103,
Karnataka, India.
E-mail: kiranmayee@
sduu.ac.in

Submitted: 15-May-2020

Revised: 16-Jul-2020

Accepted: 15-Sep-2020

Published: 23-Jul-2021

Access this article online

Website: <https://journals.lww.com/cancerjournal/pages/default.aspx>

DOI: 10.4103/jcrt.JCRT_599_20

Quick Response Code:



Cite this article as: Rani Inala MS, Pamidimukkala K. Amalgamation of quercetin with anastrozole and capecitabine: A novel combination to treat breast and colon cancers – An *in vitro* study. J Can Res Ther 2023;19:S93-105.

effects.^[9-11] Long-term treatments with quercetin result in pro-apoptotic effects that covalently link electrophilic compounds with glutathione, in particular glutathione S-transferase-P1-1 π in various cancers.^[12-15] It has been appraised in Phase I clinical trials for treating acquired mutations caused by hematological menaces as a tyrosine kinase inhibitor without side effects. Experimental attempts were in progress in gauging quercetin and its combination with classical drugs for cancer treatment.^[16,17] Therefore, quercetin extracted from unexplored sources (*Anethum graveolens* L. and *Raphanus sativus* L.) is planned for the study. *A. graveolens* (dill weed) is an annual herb of Apiaceae family with pharmacological activities such as antimicrobial, antihyperlipidemic, and antihypercholesterolemic activities.^[18] *R. sativus* is an annual root vegetable of Brassicaceae family, and the seed, root, and leaf of *R. sativus* are claimed to have several medicinal properties.^[19] With this background, the study is aimed to crack the chemotherapeutic potential of quercetin extracted from leaves of *A. graveolens* and *R. sativus* with anastrozole and capecitabine combinations in treating breast and colon cancers.

MATERIALS AND METHODS

Plant materials

The plants used for quercetin extraction were *A. graveolens* L. and *Raphanus sativus* L. grown in herbal garden. The plants were identified by Dr. Madhava Shetty, Assistant Professor, Department of Botany, S. V. University, Tirupathi, with a voucher specimen numbers of 1236 (*A. graveolens*) and 2232 (*R. sativus*). The water-stressed leaf material was collected during morning hours, dried, powdered, and stored in separate containers for further analysis.

Isolation and identification of quercetin

For solvent extraction, about 25 g of leaf powder was taken in 100 ml ethanol, kept on constant shaking at 120–130 rpm for 48 h. The residue was filtered using Whatman number 1 filter paper followed by evaporating remaining solvent in an air-circulating oven at 54°C until total dryness. About 12 g of obtained dried extract was collected and stored at 4°C for further analysis.^[20] Column chromatography by gradient elution methods was performed according to established methods available.^[21,22] About 100 mg of extract was loaded on the column (Silica) and was run with suitable solvents such as hexane, ethanol, and ethyl acetate in various combinations such as 1:1, 1:2, and 1:5 and the eluents were separately collected with 2 min time interval. The obtained fractions were pooled, concentrated, and used for checking purity by advanced chromatography, i.e., high-performance liquid chromatography (HPLC) along with the standard quercetin.

Cells and chemicals

Breast cancer cell line, Michigan Cancer Foundation-7 (MCF-7), and Colorectal adenocarcinoma cell line, COLO 320 of adherent type, were acquired from the National Centre for Cell Science,

Pune. The cell culture medium [high glucose DMEM (#AL111) and fetal bovine serum (# RM10432)] were obtained from Hi media. Anastrozole and capecitabine drugs were procured from Sigma-Aldrich and remaining solvents used were of analytical grade.

Determination of cytotoxicity

Cell lines of breast (MCF-7) and colon cancer (COLO 320) were grown individually and experiments were performed.^[23] Briefly, 200 μ l of cell suspension (2×10^4 cells/mL) was added per well in a 96-well plate and grown for 24 h. Initial experiments were performed with quercetin with concentrations ranging from 10 to 50 μ g/ml, as the cytotoxicity of compound is found to be effective with increasing concentrations, and further experiments were planned with higher concentrations. The test compound (quercetin) extracted from both the plants and standard drugs (anastrozole and capecitabine) at 50 μ g/ml, 100, 150, 200, and 250 μ g/ml concentrations was made individually, added into well of 100 μ l each, and incubated in a 5% CO₂ incubator for 24, 48, and 72 h. The media were removed and (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) was added to a final concentration of 0.5 mg/ml of total volume and incubated for 2 h. Later, MTT was removed followed by addition of 100 μ l DMSO for solubilization and absorbance was measured at 570 nm and IC₅₀ was determined. The same experiment was repeated for combination of plant quercetin, standard quercetin, and standard drugs at similar concentrations in 1:1 ratio. Absorbance was recorded at 570 nm and IC₅₀ values were determined and the IC₅₀ value obtained at 72 h time interval was considered for rest of the experiments [Table 1].

Dual stain method

Cell lines of MCF-7 and COLO 320 were cultured to a concentration of 2×10^4 /ml and dispensed into a 96-well plate of 100 μ l into each well separately.^[24] The seeded cells were treated with the combination mentioned in Table 1 and was incubated for 72 h followed by addition of 0.25% trypsin. When cells had sloughed off, 25 μ l was taken onto glass slide and added 1 μ l dual fluorescent staining solutions containing 100 μ l/ml acridine orange (AO) and 100 μ g/ml ethidium bromide (EB)

Table 1: Concentration of test and drug combinations presented in the study

Treatment groups
Cell control: only cells
Standard control (standard): Anastrozole/capecitabine
S1 (quercetin from <i>A. graveolens</i>)
S2 (quercetin from <i>R. sativus</i>)
S1 + standard control
S2 + standard control
Concentrations
Standard control (anastrozole) at 38 μ g/ml on breast cancer
Standard control (capecitabine) at 45 μ g/ml on colon cancer
S1 + anastrozole at 16 μ g/ml on breast cancer (MCF-7)
S2 + anastrozole at 31 μ g/ml on breast cancer (MCF-7)
S1 + capecitabine at 43 μ g/ml on colorectal cancer (COLO 320)
S2 + capecitabine at 46 μ g/ml on colorectal cancer (COLO 320)

MCF-7=Michigan Cancer Foundation-7

and covered with coverslip. The morphology of apoptotic cells was examined and cells were counted within 20 min under a fluorescent microscope. The observations were noted after the repetition of experiments for three times.

Cell cycle assay

Cancer and control cells (free of drug) in a 6-well plate with a cell density of $2 \times 10^5/2$ ml were incubated for 24 h in a CO₂ incubator followed by treatment with required concentration of combinational compound [Table 1] and incubated for 72 h.^[25] Later, medium left in the plates was removed, washed with phosphate-buffered saline (PBS), and decanted. Two ml culture medium was added to all the wells containing cells and harvested directly into 12 mm × 7 mm polystyrene tubes and centrifuged at $300 \times g$ at 25°C for 5 min, decanted the supernatant, and sweep up with PBS. Then, cells were fixed in 1 ml of cold 70% ethanol dropwise and mixed thoroughly to avoid clumping. Further, cells were fixed for at least 30 min on ice and pelleted at high speed compared to live cells for 5 min. Aspirated the supernatant carefully and washed twice with PBS. To ensure the DNA staining, pelleted cells were treated with 50 µl ribonuclease A to get rid of RNA. To each tube, propidium iodide (PI) of 400 µl/million cells was added, mixed, and incubated for 5–10 min at room temperature. Samples were analyzed by flow cytometry in PI solution without washing.

Mitochondrial membrane potential analysis

Cancer cells were maintained in a 6-well plate with a cell density of $3 \times 10^5/1$ ml and incubated for 24 h at 37°C in a CO₂ incubator.^[26] Cells were treated with the combination of quercetin and drug as mentioned (table 1) and incubated for 72 h. At the end of treatment, cells were transferred into 12 mm × 75 mm polystyrene tubes and centrifuged at $300 \times g$, 25°C for a period of 5 min. The upper layer was decanted and washed the cells with PBS. JC-1 dye (5, 5', 6, 6'-tetrachloro-1, 1', 3, 3'-tetraethylbenzimidazolyl carbocyanine iodide, 0.5 ml) was supplemented to cell pellet and incubated for 10–15 min at 37°C in a CO₂ incubator.

Caspase assay

Cancer cells were taken in a 6-well plate with a cell density of $0.5 \times 10^6/2$ ml and incubated for a period of 24 h in a CO₂ incubator at 37°C. Media was taken out and test compound and standard [Table 1] were given and incubated for 72 h.^[27] Cells were splashed with PBS, and 300 µl of trypsin-EDTA was added and incubated for 3–4 min at 37°C. Then, 2 ml of medium was supplied and cells were picked directly into 12 mm × 75 mm polystyrene tubes and centrifuged at $300 \times g$, 25°C for 5 min time period. The top layer was decanted and cells were given PBS wash twice. The PBS-free cells were fixed in 1 ml of prechilled cold 70% ethanol added dropwise and left on ice for 30 min. Cells were pelleted at high speed, supernatant was discarded followed by PBS wash. Then, 5 µl of fluorescein isothiocyanate caspase 3 antibody was added, mixed, and kept at room temperature for 30 min in dark. Cells were then washed with $1 \times$ PBS contained 0.1% sodium

azide, mixed the cells thoroughly with PBS, and analyzed by flow cytometry.

Determination of cytotoxicity on normal cell line

Mouse fibroblast cell lines, 3T3-L1, were grown in DMEM and FBS medium and 200 µl cell suspension was seeded on a 96-well plate at required cell density (2×10^4 cells). To these cells, 100 µl of different concentrations (50, 100, 150, 200, and 250 µg/ml) of standard drugs (anastrozole and capecitabine) and combination with quercetin were added. Plates were incubated for 72 h at 37°C in a 5% CO₂ atmosphere and followed by addition of MTT (0.5 mg/ml) and further incubated for 3 h. Later, 100 µl of solubilization solution (DMSO) was added to all the wells and gently stirred on a gyrator shaker and absorbance was read at 570 nm. The IC₅₀ value was determined using linear regression equation.^[23]

$Y = MX + C$ (Here, $Y = 50$, M and C values were derived from the viability graph).

Statistical analysis

The data obtained were calculated for mean $\pm$ standard deviation. The statistical differences of all the treated groups at different time intervals were determined by ANOVA (IBM SPSS Software) for comparison with various combinations of test compound and drug, $P < 0.05$ is considered as significant.

RESULTS

Identification and purification of compound

The fractions of column chromatography when subjected to HPLC depicted similar retention times for the quercetin extracted from *A. graveolens* and *R. sativus* (14.76, 14.78 min) and standard quercetin (14.45 min) as depicted in Figure 1 and considered as 98% pure.

Inhibitory outcome of quercetin and drugs on the proliferative activity of MCF-7 and COLO 320

Upon initial screening of cytotoxicity by MTT assay, IC₅₀ values for all the tested cancer cell lines of breast and colon were calculated. It was found that the IC₅₀ values of breast and colon cancer at 72 h treatment were found encouraging. Interestingly, the combination of quercetin with drugs showed less IC₅₀ value compared to standard drug treatment alone on breast and colon cancer cell lines at same time interval [Tables 2 and 3]. The results proved that quercetin extracted from *A. graveolens* and *R. sativus* in combination with anastrozole at 250 µg/ml exhibited IC₅₀ value of 16 and 31 µg/ml on breast cancer and 43 and 46 µg/ml on colon cancer. Hence, the resulted potential cytotoxic activity exhibited by combination of drug with quercetin at 72 h was taken forward to screen the mechanism of action on breast and colon cancer cell lines.

Quercetin prompts apoptosis with drug combination against MCF-7 and COLO 320

Cells of MCF-7 and COLO 320 were stained by AO/EB for 72 h




Figure 1: A: HPLC chromatogram of quercetin standard; B: HPLC chromatogram of quercetin extracted from *A. graveolens* and C: HPLC chromatogram of quercetin extracted from *R. sativus*

Table 2: Cytotoxic potential of test compounds on MCF-7 cell line at different time intervals

Test	IC50 (µg/ml)		
	For 24 h	For 48 h	For 72 h
Quercetin from <i>A. graveolens</i> (S1)	329	233	161
Quercetin from <i>R. sativus</i> (S2)	474	280	158
Anastrozole (standard)	216	134	38
S1 + standard	173	67	16*
S2 + standard	202	116	31*

ANOVA was used for comparison and *P* value was found to be significant (0.02337)

Table 3: Cytotoxic potential of test compounds on COLO 320 cell line at different time intervals

Test	IC50 (µg/ml)		
	For 24 h	For 48 h	For 72 h
Quercetin from <i>A. graveolens</i> (S1)	324	175	106
Quercetin from <i>R. sativus</i> (S2)	546	203	131
Capecitabine (standard)	194	56	45
S1 + standard	246	118	43*
S2 + standard	298	140	46*

ANOVA was used for comparison and *P* value was found to be significant (0.02337)

and were analyzed by fluorescent microscope. Quercetin from both the plants (*A. graveolens* and *R. sativus*) with anastrozole and capecitabine combination at 16 and 31 µg/ml on breast cancer and 43 and 46 µg/ml on colon cancer presented effective morphological changes like cell shrinkage and condensation of chromatin depicted in Figures 2 and 3 respectively.

Quercetin and standard drugs boost cell cycle arrest at various stages

Further to MTT assay (cell viability), growth arrest was explained by cell cycle analysis. Therefore, changes in cell cycle after 72 h of stimulation with combination of quercetin and drug using flow cytometry were assessed. Treatment of MCF-7 cells with quercetin (*A. graveolens*) and anastrozole (1:1 ratio) at 16 µg/ml concentration showed significant G1 phase arrest than the treatment with standard drug anastrozole of the similar concentration. Likewise, more number of cells were arrested in G2/M phase at 16 and 31 µg/ml concentrations of quercetin from *A. graveolens* and *R. sativus*, which is more significant than the G2/M arrest exhibited by standard drug, a novel identification. No significant differences were noted in SubG0/G1 (Apoptotic phase) of cell cycle in test compounds, but in standard control, it showed significant increase compared to cell control as depicted in Figure 4.



Figure 2: Acridine orange/ethidium bromide staining of *in vitro* grown cultures of MCF-7 cells in treatment with test compound and standard drug




Figure 3: Acridine orange/Ethidium Bromide staining of *in vitro* grown cultures of Colo 320 cells in treatment with test compound and standard drug




Figure 4: Propidium iodide histogram of the gated cell singlets distinguishes cells at the sub G0/G1, G0/G1, S and G2/M cycle phases and images of flow cytometric analysis showing cell control (a), standard control (anastrozole) (b), quercetin from *A. graveolens* + anastrozole (S1 + standard control) (c) and quercetin from *R. sativus* + anastrozole (S2 + standard control) (d) respectively against MCF-7 cells

The results of cell cycle by flow cytometry on COLO 320 cells suggested that compared to cell control, drug treatment of test compounds (namely quercetin from *A. graveolens* L. at 43 µg/ml concentration [S1 + standard] and quercetin from *R. sativus* L. at 46 µg/ml concentration [S2 + standard]) clearly established cell cycle arrest in Sub G0/G1, G0/G1 phase and also G2/M phase of cell cycle. There were no significant differences noticed in S (synthetic phase) of cell cycle in test compounds and standard control compared to cell control. This seems to be the first report to knock out the novel drug combinations with quercetin that effectively arrest the cell cycle at different phases at minimal concentrations as shown in Figure 5.

Quercetin induces depolarization to mitochondrial membrane potential

A sensitive cationic and lipophilic JC-10 fluorescent probe was preferred to monitor the mitochondrial membrane potential alteration in the cells. Quercetin combination with drugs showed a significant reduction of mitochondrial membrane integrity against MCF-7 and COLO 320 cells by showing the shift of cells from upper right quadrant-red (FL2) to lower right quadrant-green (FL1). The obtained results clearly suggest that the mitochondrial depolarization happened in MCF-7 and COLO 320 by the action of the compounds, led to cell death. It resulted an observation that compound S1 (quercetin from *A. graveolens*) has significant mitochondrial

membrane depolarization/integrity potential compared S2 (quercetin from *R. sativus*) by conjugating with standard drugs in the ratio of 1:1 against MCF-7 and COLO 320 cell lines after incubating for 72 h as shown in Figures 6-9.

Quercetin with anastrozole and capecitabine combination induces activation of expression of caspase 3

The observations in statistical data of caspase 3 expression by a technique called flow cytometry suggest that caspase 3 level is very low in untreated MCF7 Cells (8.82 mean fluorescence intensity [MFI]) compared to anastrozole (41.33 MFI) after the incubation period of 72 h. The test compounds (S1 + anastrozole and S2 + anastrozole) showed caspase 3 expression at 37.82 and 32.10 in terms of MFI after 72 h of incubation [Table 4 and Figure 10].

The observations in statistical data of caspase 3 expression indicate that it expresses very low in untreated COLO-320 cells (8.69MFI) compared to capecitabine (61.88MFI) after the incubation period of 72 h. The test compounds (S1 + capecitabine and S2 + capecitabine) showed caspase 3 expression at 47.79 and 42.45 MFI after 72 h of incubation [Table 5 and Figure 11].

The nontoxic nature of combinational treatment on normal cell line, 3T3-L1

The cytotoxic effect of quercetin in combination with




Figure 5: Propidium iodide histogram of the gated cell singlets distinguishes cells at the sub G0/G1, G0/G1, S and G2/M cycle phases and images of flow cytometric analysis showing cell control (a), standard control (capecitabine) (b), quercetin from *A. graveolens* + capecitabine (S1 + standard control) (c) and quercetin from *R. sativus* + capecitabine (S2 + standard control) (d) respectively against COLO 320 cells




Figure 6: JC1 expression study of MCF-7 cell line by flow cytometry. The quadrants depicting mitochondrial membrane depolarization in different groups viz., cell control (a), standard control (anastrozole) (b), S1 + Standard (c) and S2 + standard (d) with IC50 concentrations




Figure 7: Histogram showing the healthy and damaged mitochondrial cells upon treatment with combination of anastrozole and quercetin from *A. graveolens* (S1) and *R. sativus* (S2) standard against Michigan Cancer Foundation-7 cells

anastrozole and capecitabine was evaluated on 3T3-L1. The results showed that the combination of quercetin and standard drugs were not cytotoxic to normal cells even after 72 h of incubation at IC₅₀ above 100 µg/ml and up to 250 µg/ml [Figure 12]. The final conclusion drawn from the study suggests that S1(quercetin from *A. graveolens*) and S2 (quercetin from *R. sativus*) in combination with standard drugs on 3T3-L1 cell lines exhibited IC₅₀ values greater than the IC₅₀ values obtained on MCF-7 and COLO-320 cancer cell lines after the incubation period of 72 h. Hence, it is proved that quercetin does not have any cytotoxicity against mouse normal fibroblast cells (3T3-L1).

DISCUSSION

It is observed that only 10% of plant types are investigated for pharmacological benefits out of 250,000 species. We used the leaves for quercetin isolation as nearly 25% of modern drugs are derived from plants. The leaves can be consumed as salad and also as one of the ingredients in Indian cuisine. Hence, plant-based quercetin can be incorporated into the system directly rather than using commercial quercetin. These two plants are also added in the literature along with the other available plant sources for quercetin.^[28] The phytochemicals of various parts of plant such as phenolics,

Table 4: Mean fluorescence intensity of caspase 3 against the untreated, standard control (anastrozole) and the combination of anastrozole with the test compounds, S1 and S2 with the ratio of 1:1 treated on MCF-7 cells

Caspase 3	Relative mean fluorescence intensity y.a.u (arbitrary units of fluorescence)
Cell control	8.82
Anastrozole	41.33
S1 + anastrozole	37.82
S2 + anastrozole	32.1

Table 5: Mean fluorescence intensity of caspase 3 against the untreated, standard control (capecitabine) and the combination of capecitabine with the test compounds S1 and S2 with the ratio of 1:1 treated on COLO 320 cells

Caspase 3	Relative mean fluorescence intensity y.a.u (arbitrary units of fluorescence)
Cell control	8.69
Capecitabine	61.88
S1 + capecitabine	47.79
S2 + capecitabine	42.45

alkaloids, flavonoids, glycosides, gums, resins, and oils are the prioritized constituents for anticancer potential.^[29] Flavonoids are the abundant components with varied biological activities. They belong to polyphenol groups having 3-hydroxyflavone backbone with quercetin, kaempferol, and myricetin subgroups. Literature revealed 9,000 different flavonoids, of which their daily intake differs between 20 mg and 500 mg from dietary supplements.^[30] Quercetin is copious in plants, fruits, and vegetables and exists in aglycone or in bounded form with carbohydrates and alcohols.^[31-33] It is assumed as strong antioxidant with its free radical scavenging activity that binds to metal ions.^[34,35] This oxidative damage to DNA is measured as a risk factor that amounts for cancer.^[36] Quercetin acts as a strong antioxidant in cells via limiting the reactive oxygen and nitrogen species that help in cancer development.

It was illustrious that till date, 350 quercetin glycones were reported from various plant sources.^[37] Therefore,




Figure 8: JC1 expression study of COLO 320 cell line by flow cytometry. The quadrants depicting mitochondrial membrane depolarization in different groups viz., cell control (a), standard control (capecitabine) (b), S1 + standard (c) and S2 + standard (d) with IC50 concentrations




Figure 9: Histogram showing the healthy and damaged mitochondrial cells upon treatment with combination of capecitabine and quercetin from *A. graveolens* (S1) and *R. sativus* (S2) against COLO 320 cells

the identification of quercetin from diversified plant groups (*A. graveolens* L. and *Raphanus sativus* L) helps in detecting new sources of quercetin as medicine and food supplement. Leaf is considered for quercetin extraction and the portion retained from column chromatography is tested for purity by HPLC and related with standard. For the present study, leaves were used for isolation of quercetin, since leaves contain more quercetin content based on the other observations.^[38] HPLC of column chromatography fractions eluted at retention time of 14.45 (standard) and 14.76 (quercetin from *A. graveolens*) and 14.78 (*R. sativus*). The HPLC elution time of quercetin fraction is in coordination with tomato-based products and *Marchantia convolute*.^[39,40] As quoted earlier about the benefits of quercetin, several *in vitro* reports proved that quercetin can minimize extent of the tumor in voluminous cancer cells by its capability to induce apoptosis that makes it an important phytochemical in treating cancer. The study investigations were able to fill the existing gap of novel identified resources from edible greens, which will have additional benefit to human community upon consumption.

The American Cancer Society estimates 2.1 million newly approved breast cancers and 1.8 million colorectal cancers

worldwide.^[41,42] Treatment choices for cancers involve radiation and hormone therapy, surgery, and chemotherapy. Among several methods, chemotherapy is considered as the main line of treatment used before or after surgery. This chemotherapy involves only monotherapeutic agents and/or in relation with other agents to destroy cancer cells. However, chemotherapy limits its application by dose-limiting toxicity, difficulty in drug delivery of hydrophobic drugs, and resistance.^[43] Cancer cells undergo complex molecular pathway; application of monotherapy brings cancer cells to use alternative pathways for recurrence.^[44] This has resulted in metastasis and drawn our attention to focus on combination therapy which aids to overcome resistance and also aids to reduce dose of each agent.^[45]

Multiple regimen targets are in practice for handling breast cancer and colorectal cancer. Anastrozole with trade name Arimidex is a potent nonsteroidal aromatase inhibitor employed for altered stages of breast cancer treatment since 1995.^[46] The treatment with anastrozole should be long till the tumor regression ends. The anticancer therapy with anastrozole leads to adverse effects such as anemia, vaginal bleeding, skeletal complications, sexual dysfunction, and leucopenia.^[47] Capecitabine a first-line medicine for colorectal cancer is commercially called as Capiibine since 1998. The adverse drug effects include chest pain, low platelet count, back pain, anemia, and jaundice.^[48] Keeping in view of side effects caused by available drugs, much research is going on to minimize its effects, which is indeed presented in the study reports. For various natural sources, a precise mechanism of action is not known and being investigated. Quercetin from *A. graveolens* and *R. sativus* falls into such category where its mechanism of action and also its combination by drugs is not being reported in literature.

Food is the foremost source of bioactive components that benefit us; the combination of food components having biological efficacy with drug might reduce the toxic burden on the patient undertaking treatment. Reports in the study proved that quercetin had higher efficacy for breast and colon cancer with inhibitory concentration from 106 µg/ml to 131 µg/ml on colon cancer and 161 µg/ml to 158 µg/ml on breast




Figure 10: Caspase 3 expression study of cell control/untreated cells (a), Standard control (anastrozole) (b), quercetin from *A. graveolens* + anastrozole (S1 + standard control) (c) and quercetin from *R. sativus* + anastrozole (S2 + standard control) (d) respectively against MCF-7 cells




Figure 11: Caspase 3 expression study of cell control/untreated cells (a), Standard control (capecitabine) (b), quercetin from *A. graveolens* + capecitabine (S1 + standard control) (c) and quercetin from *R. sativus* + capecitabine (S2 + standard control) (d) respectively against COLO 320 cells




Figure 12: Cytotoxic activity of anastrozole and capecitabine in combination with plant quercetin on 3T3-L1 cells

cancer [Figure 2]. Upon combination with standard drug, quercetin significantly enhanced its efficacy with an IC50 concentration <50 µg/ml, which is an ideal concentration to be considered for formulation of any drug. This is in agreement

with other studies, stating that quercetin improved its potency with drugs such as cisplatin, doxorubicin, camptothecin, 5-fluorouracil, sorafenib, oxaliplatin, and gemcitabine against various kinds of cancers.^[49-53] With growing research interest, we appealed foremost to demonstrate the impression of quercetin in combination with anastrozole, a breast cancer drug, and capecitabine, a colon cancer drug in the study.

Natural compounds which control tumor cell proliferation via controlling mitosis and cell cycle are important candidates for application in basic and translational research before going to clinical trials. As uncontrolled and rapid cell division is a hallmark of cancer, untying the molecular mechanism of mitosis is key to understand how natural compounds function as antimitogenic agents.^[54,55] Alkaloids and colchicine are known to block mitotic phase in cell cycle that are reported to inhibit cell proliferation in cancer of testicles and lymphocytic leukemia.^[56-58] In the present study report, the combination of quercetin fraction and anastrozole and capecitabine

induced metaphase and S phase arrest in breast cancer. This observation looks to be a reason for a novel finding presented in Figures 5 and 6. The resulted findings were in agreement with similar study reports where quercetin blocked S phase arrest. However, reports derived from other studies convey that difference in the cancer types and application of compound might account for disparity in the observation of variation of cell cycle arrest.^[59-65]

The combination of quercetin with ellagic acid lessened proliferation and cell cycle arrest in MOLT-4 cells of leukemia.^[66-68] Quercetin with doxorubicin combination had a significant decrease in cell proliferation in MCF-7 and MDA-MB-231. However, in the present study, the combination of quercetin with anastrozole and capecitabine at low concentration revealed a significant antiproliferative activity, a unique observation than other reports. Another study also proved that quercetin narrowed T47D breast cancer cell lines sensitivity with an IC50 value at 160 μ M.^[69] Quercetin on ovarian cancer cells showed G2/M phase arrest at 100 μ g/ml concentration.^[70] In the present study, quercetin in combination with anastrozole showed G2/M and S phase arrest on breast cancer at 16 μ g/ml concentration; quercetin in combination with capecitabine showed G0/G1 and G2/M phase arrest at 43 μ g/ml concentration on colon cancer. This is the first report of using the lowest concentration and combination on the selected cell lines. The advances in understanding the cell cycle mechanism by chemotherapeutic agents are of significant importance for improving efficacy of targeted combinational therapies with natural compounds. This helps to overcome resistance to anticancer drugs involved in cell cycle leading to cell proliferation.

Mitochondrial membrane potential is a dominant driving force for ATP synthesis. In various cancer cells, mitochondria become dysfunctional via changes in energy metabolism, elevated reactive oxygen species generation, and increased transmembrane potential. Hence, targeting mitochondria using pharmacological agents is an attractive therapeutic strategy to destroy cancer cells.^[71] Quercetin cotreatment with autophagy inhibitor enhanced mitochondrial damage and autophagy inhibition in Jurkat T-cells.^[72] Isorhamnetin glycoside (IGP) from *Puntia ficus-indica* L. Mill on colon cancer implied membrane permeabilization of 30% and G2/M phase arrest, which is similar to our study results as shown in Figures 7-10.^[73] Quercetin contributes protection against mitochondrial impairment in an *in vitro* model of hepatocyte steatosis.^[74] A study reports that quercetin acts via mitochondrial pathway in cervical cancer cells through p53 induction and NF- κ B inhibition at 80 μ M. However, we demonstrated enhanced effect of quercetin with anastrozole and capecitabine on lower doses on breast (16 and 31 μ g/ml) and colon cancer (43 and 46 μ g/ml).^[75] The study investigations made on quercetin with curcumin combination presented apoptotic induction in chronic leukemia cells that lowered toxic effects on normal cells.^[76] The same combination had also impact on apoptosis through mitochondrial pathway on gastric cancer MGC-803 cells, indicating that

the combination has better potential.^[77] These results are on par with our study results where combinations (quercetin and anastrozole combination, quercetin, and capecitabine) showed decreased cell proliferation, apoptosis through acting on mitochondrial mechanism on breast and colon cancer cells, a novel combination.

As reported in the literature, disruption in the mitochondrial potential leads to an increase in mitochondrial permeability that leads to release of pro-apoptotic proteins such as growth factors, cytokines, and caspases.^[78] Caspases are crucial mediators of programmed cell death and among them caspase 3 is frequently activated death protease in different cell types. Caspase 3 also has a central role in execution-phase of apoptosis in addition to caspase 7.^[79] The central role of caspase 3 makes the molecule an attractive target and attempts were continuous from decades to develop molecules to activate caspase 3. Therefore, screening the phytochemical compounds having caspase activity will have a significant role in cancer treatment. The study findings illustrate that quercetin with drugs initiates caspase 3 on MCF-7 and COLO 320 cancer cells. In another finding, tangeretin flavone displayed cell cycle arrest and caspase activation in MDA-MB-231 breast carcinoma cells.^[80] By focusing on caspase 3 activation, a hallmark of apoptosis, cell death activators and inhibitors can be studied. In a study, quercetin induced apoptosis via activation of caspases in human hepatoma cell line HepG2.^[81] They also reported that a continuous daily intake of polyphenols like quercetin might provoke apoptotic cell death. As caspase 3 plays a central role in execution-phase of cell apoptosis, attempts were continuous from the decade to develop molecules capable of directly activating caspase 3 for treatment use in cancer therapy.^[82] The present study results were impressive where caspase activation was achieved at lower concentrations of the tested combinations on breast and colon cancers.

Even though in recent times, we find many treatment options for patients with cancer, a successful treatment with anticancer drugs remains a challenge due to nonselective cytotoxicity of the drugs. Overall, chemotherapy with cytotoxic and cytostatic drugs remains the primary treatment option. In addition, chemotherapeutic agents available today are highly cytotoxic to normal cells, resulting in a series of adverse effects.^[83] A promising new compound in anticancer therapy is based not only on its ability to induce tumor cell death but also its selectivity, i.e., on its capacity to minimally affect normal cells.^[84] The results of the study suggest that plant quercetin when combined with synthetic drugs is highly selective in cancer treatment by showing no toxicity toward normal cell lines when compared to cancer cell lines (3T3-L1). Hence, this combination can be a model for the development of new drugs to be used in clinical trials in the future, when tested on other models.

CONCLUSIONS

Natural flavonol fraction 'quercetin' with most potential

biological importance is identified from unexplored plant sources. Effective research on combination of natural component with available drugs on the top most cancers is useful for reducing the adverse toxic side effects related with conventional chemotherapy. The strength of the study is that it turns to be first report to rule out the combination of anastrozole and capecitabine with natural active component, quercetin, which creates an avenue for knocking new drug combinations. The limitation of the study is that we could get limited cell lines from NCCS Pune for carrying out the work.

Acknowledgments

We are grateful to our department for providing all the facilities and infrastructure required for our research work.

Financial support and sponsorship

Department of Cell Biology and Molecular Genetics.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, *et al.* Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* 2019;144:1941-53.
2. Gottesman MM, Lavi O, Hall MD, Gillet JP. Toward a better understanding of the complexity of cancer drug resistance. *Annu Rev Pharmacol Toxicol* 2016;56:85-102.
3. Hanahan D. Rethinking the war on cancer. *Lancet* 2014;383:558-63.
4. Hortobagyi GN. Treatment of breast cancer. *N Engl J Med* 1998;339:974-84.
5. Miller WR, Larionov AA. Understanding the mechanisms of aromatase inhibitor resistance. *Breast Cancer Res* 2012;14:201.
6. Kümler I, Knoop AS, Jessing CA, Ejlersen B, Nielsen DL. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. *ESMO Open* 2016;1:e000062.
7. National Comprehensive Cancer Network The NCCN Clinical Practice Guidelines in Oncology: Colon Cancer (Version 2.2011); 2010. Available from: http://www.nccn.org/professionals/physician_gls/recently_updated.asp. [Version 4.2018, October 19, 2018]
8. National Comprehensive Cancer Network the NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (Version 2.2011); 2010. Available from: http://www.nccn.org/professionals/physician_gls/recently_updated.asp. [Version 3.2018, August 7, 2018]
9. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. *Breast Cancer Res Treat* 2003;77:171-83.
10. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, *et al.* Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for *in vivo* tyrosine kinase inhibition. *Clin Cancer Res* 1996;2:659-68.
11. Moon YJ, Wang L, DiCenzo R, Morris ME. Quercetin pharmacokinetics in humans. *Biopharm Drug Dispos* 2008;29:205-17.
12. Lo HW, Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. *Curr Opin Pharmacol* 2007;7:367-74.
13. Tsuchida S, Sato K. Glutathione transferases and cancer. *Critic Rev Biochem Mol Biol* 1992;27:337-84.
14. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. *Annu Rev Pharmacol Toxicol* 2005;45:51-88.
15. Huang J, Tan PH, Thiyagarajan J, Bay BH. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. *Mod Pathol*. 2003;16:558-65.
16. Akbas SH, Timur M, Ozben T. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells. *J Surg Res* 2005;125:49-55.
17. Schlachterman A, Valle F, Wall KM, Azios NG, Castillo L, Morell L, *et al.* Combined resveratrol, quercetin, and catechin treatment reduces breast tumour growth in a nude mouse model. *Transl Oncol* 2008;1:19-27.
18. Delaquis PJ, Stanich K, Girard B, Mazza G. Antimicrobial activity of individual and mixed fractions of dill, cilantro, coriander and eucalyptus essential oils. *Int J Food Microbiol* 2002;74:101-9.
19. Aziz F, Hassan D. Radish juice promote kidney stone deposition in ethylene glycol-induced urolithiasis in rats. *Cihan Univ Erbil Scient J* 2020;4:57-61.
20. Anyasor GN, Ogunwenmo KO, Oyelana OA, Akpofunure BE. Phytochemical constituents and antioxidant activities of aqueous and methanol stem extracts of *Costus afer* Ker Gawl. (Costaceae). *Afr J Biotechnol* 2010;9:4880-84.
21. Assam AJ, Dzoyem JP, Pieme CA, Penlap VB. *In vitro* antibacterial activity and acute toxicity studies of aqueous-methanol extract of *Sida rhombifolia* Linn. (Malvaceae). *BMC Complementary Alternative Med* 2010;10:1-7.
22. Lawrence O, Manguro A, Ugi L, Lemmen P. Flavonol glycosides from the leaves of *Embelia keniensis*. *J Chin Chem Soc* 2013;5:201-8.
23. Juillerat-Jeanneret L, Bernasconi CC, Bricod C, Gros S, Trepey S, Benhattar J, *et al.* Heterogeneity of human glioblastoma: Glutathione-S-transferase and methyl guanine-methyltransferase. *Cancer Invest* 2008;26:597-609.
24. Lecoœur H. Nuclear apoptosis detection by flow cytometry: Influence of endogenous endonucleases. *Exp Cell Res* 2002;277:1-4.
25. Cárdenas MG, Blank VC, Marder M, Roguin LP. 2'-Nitroflavone induces cell cycle arrest and apoptosis in HeLa human cervical carcinoma cells. *Cancer Lett* 2008;268:146-57.
26. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). *Biochem Biophys Res Commun* 1993;197:40-5.
27. Dai C, Krantz SB. Interferon gamma induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. *Blood* 1999;93:3309-16.
28. Tariq A, Sadia S, Pan K, Ullah I, Mussarat S, Sun F, *et al.* A systematic review on ethnomedicines of anti-cancer plants. *Phytother Res* 2017;31:202-64.
29. Singh S, Jarial R, Kanwar SS. Therapeutic effect of herbal medicines on obesity: Herbal pancreatic lipase inhibitors. *Wud Pecker J Med Plants* 2013;2:53-65.
30. Farhadi F, Khameneh B, Iranshahi M, Iranshahi M. Antibacterial activity of flavonoids and their structure-activity relationship: An update review. *Phytother Res* 2019;33:13-40.
31. Ramos S. Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways. *Mol Nutr Food Res* 2008;52:507-26.
32. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. *J Nutr* 2000;130:2073S-85S.
33. Sultana B, Anwar F. Flavonols (kaempferol, quercetin, myricetin) contents of selected fruits, vegetables and medicinal plants. *Food Chem* 2008;108:879-84.
34. Hollman PC, van Trijp JM, Mengelers MJ, de Vries JH, Katan MB. Bioavailability of the dietary antioxidant flavonol quercetin in man. *Cancer Lett* 1997;114:139-40.
35. Sakanashi Y, Oyama K, Matsui H, Oyama TB, Oyama TM, Nishimura Y, *et al.* Possible use of quercetin, an antioxidant, for protection of cells suffering from overload of intracellular Ca²⁺: A model experiment.

- Life Sci 2008;83:164-9.
36. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. *Biochem J* 1996;313 (Pt 1):17-29.
 37. Yoon JA, Kim BG, Lee WJ, Lim Y, Chong Y, Ahn JH. Production of a novel quercetin glycoside through metabolic engineering of *Escherichia coli*. *Appl Environ Microbiol* 2012;78:4256-62.
 38. Holderbaum DF, Kon T, Guerra MP. Dynamics of total phenolic content in different apple tissues and genotypes: Impacts and relevance for breeding programs. *Sci Horticul* 2014;168:58-63.
 39. Tokusoglu O, Unal MK, Yildirim Z. HPLC-UV and GC-MS characterization of the flavonol aglycons quercetin, kaempferol and myricetin in tomato pastes and other tomato-based products. *Acta Chromatogr* 2003;13:196-207.
 40. Xiao-qing C, Jian-bo X. RP-HPLC-DAD determination of flavonoids: Separation of quercetin, luteolin and apigenin in *Marchantia Convoluta*. *Iran J Pharm Res* 2005;4:175-81.
 41. American Cancer Society. How Common Is Breast Cancer? American Cancer Society; 2017. Available from: <https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html#references>. [Last accessed on 2017 Aug 27].
 42. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut* 2017;66:683-91.
 43. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, *et al*. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. *Clin Cancer Res* 2003;9:827-36.
 44. Meng J, Guo F, Xu H, Liang W, Wang C, Yang XD. Combination therapy using Co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells *in vivo*. *Sci Rep* 2016;6: 1-11.
 45. Ren Y, Wang R, Gao L, Li K, Zhou X, Guo H, *et al*. Sequential co-delivery of miR-21 inhibitor followed by burst release doxorubicin using NIR-responsive hollow gold nanoparticle to enhance anticancer efficacy. *J Con Release* 2016;228:74-86.
 46. Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: Challenges and opportunities. *J Control Release* 2013;170:15-40.
 47. Goss PE, Tye LM. Anastrozole: A new selective nonsteroidal aromatase inhibitor. *Oncology (Williston Park)* 1997;11:1697-703.
 48. Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: A phase II trial. *Cancer* 2004;100:531-7.
 49. Chan ST, Yang NC, Huang CS, Liao JW, Yeh SL. Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression *in vitro* and *in vivo*. *PLoS One* 2013;8:e54255.
 50. Li J, Zhu F, Lubet RA, De Luca A, Grubbs C, Ericson ME, *et al*. Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis. *Mol Carcinog* 2013;52:134-43.
 51. Jakubowicz-Gil J, Langner E, Bądziul D, Wertel I, Rzeski W. Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. *Neurotox Res* 2014;26:64-77.
 52. Kavithaa K, Sumathi S, Paulpandi M, Padma P. Increased anticancer efficacy by the combined administration of quercetin in multidrug resistant breast cancer cells. *Adv Cancer Res* 2014;1-13.
 53. Zhao JL, Zhao J, Jiao HJ. Synergistic growth-suppressive effects of quercetin and cisplatin on HepG2 human hepatocellular carcinoma cells. *Appl Biochem Biotechnol* 2014;172:784-91.
 54. Rao CV, Kurkjian CD, Yamada HY. Mitosis-targeting natural products for cancer prevention and therapy. *Curr Drug Targets* 2012;13:1820-30.
 55. Dall'Acqua S. Natural products as antimitotic agents. *Curr Top Med Chem* 2014;14:2272-85.
 56. Palmer CG, Livengood D, Warren AK, Simpson PJ, Johnson IS. The action of the Vinca leukolastine on mitosis *in vitro*. *Exp Cell Res* 1960;20:198-201.
 57. Wani MC, Taylor HL, Nall ME, Caggon P, Mc Phail AT. Plant anti-tumor agents VI. The isolation and structure of taxol, a novel anti-leukemic and anti-tumor agents from *taxus brevifolia*. *J Ayur Med Chem Soc* 1971;93:2325-7.
 58. Mukhtar E, Adhami VM, Mukhtar H. Targeting microtubules by natural agents for cancer therapy. *Mol Cancer Ther* 2014;13:275-84.
 59. Zhang H, Zhang M, Yu L, Zhao Y, He N, Yang X. Antitumor activities of quercetin and quercetin-5',8-disulfonate in human colon and breast cancer cell lines. *Food Chem Toxicol* 2012;50:1589-99.
 60. Yuan Z, Long C, Junming T, Qihuan L, Youshun Z, Chan Z. Quercetin-induced apoptosis of HL-60 cells by reducing PI3K/Akt. *Mol Biol Rep* 2012;39:7785-93.
 61. Yoshida M, Yamamoto M, Nikaido T. Quercetin arrests human leukemic T-cells in late G1 phase of the cell cycle. *Cancer Res* 1992;52:6676-81.
 62. Richter M, Ebermann R, Marian B. Quercetin-induced apoptosis in colorectal tumor cells: Possible role of EGF receptor signaling. *Nutr Cancer* 1999;34:88-99.
 63. Choi JA, Kim JY, Lee JY, Kang CM, Kwon HJ, Yoo YD, *et al*. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. *Int J Oncol* 2001;19:837-44.
 64. Lee TJ, Kim OH, Kim YH, Lim JH, Kim S, Park JW, *et al*. Quercetin arrests G2/M phase and induces caspase-dependent cell death in U937 cells. *Cancer Lett* 2006;240:234-42.
 65. Zhang Q, Zhao XH, Wang ZJ. Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. *Food Chem Toxicol* 2008;46:2042-53.
 66. Mertens-Talcott SU, Percival SS. Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. *Cancer Lett* 2005;218:141-51.
 67. Mertens-Talcott SU, Talcott ST, Percival SS. Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. *J Nutr* 2003;133:2669-74.
 68. Staedler D, Idrizi E, Kenzaoui BH, Juillerat-Jeanneret L. Drug combinations with quercetin: Doxorubicin plus quercetin in human breast cancer cells. *Cancer Chemother Pharmacol* 2011;68:1161-72.
 69. Srivastava S, Somasagara RR, Hegde M, Nishana M, Tadi SK, Srivastava M, *et al*. Quercetin, a natural flavonoid interacts with DNA, arrests cell cycle and causes tumor regression by activating mitochondrial pathway of apoptosis. *Sci Rep* 2016;6:24049.
 70. Wang Y, Han A, Chen E, Singh RK, Chichester CO, Moore RG, *et al*. The cranberry flavonoids PAC DP-9 and quercetin a glycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. *Int J Oncol* 2015;46:1924-34.
 71. Lu W, Ogasawara MA, Huang P. Models of reactive oxygen species in cancer. *Drug Discov Today Dis Models* 2007;4:67-73.
 72. Ha EJ, Kim KY, Kim CE, Jun DY, Kim YH. Enhancement of quercetin-induced apoptosis by cotreatment with autophagy inhibitor is associated with augmentation of BAK-dependent mitochondrial pathway in Jurkat T cells. *Oxid Med Cell Long* 2019;2019:1-16.
 73. Antunes-Ricardo M, Hernández-Reyes A, Uscanga-Palomeque AC, Rodríguez-Padilla C, Martínez-Torres AC, Gutiérrez-Urbe JA. Isorhamnetin glycoside isolated from *Opuntia ficus-indica* (L.) Mill induces apoptosis in human colon cancer cells through mitochondrial damage. *Chem Biol Interact* 2019;310:1-8.
 74. Rafiei H, Omidian K, Bandy B. Phenolic Breakdown Products of Cyanidin and Quercetin Contribute to Protection against Mitochondrial Impairment and Reactive Oxygen Species Generation

- in an *In vitro* Model of Hepatocyte Steatosis. *J Agric Food Chem* 2019;67:6241-7.
75. Vidya Priyadarsini R, Senthil Murugan R, Maitreyi S, Ramalingam K, Karunakaran D, Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF- κ B inhibition. *Eur J Pharmacol* 2010;649:84-91.
 76. Mutlu Altundağ E, Yılmaz AM, Koçtürk S, Taga Y, Yalçın AS. Synergistic Induction of apoptosis by quercetin and curcumin in chronic myeloid leukemia (K562) cells. *Nutr Cancer* 2018;70:97-108.
 77. Zhang JY, Lin MT, Zhou MJ, Yi T, Tang YN, Tang SL, *et al.* Combinational Treatment of Curcumin and Quercetin against Gastric Cancer MGC-803 Cells *in vitro*. *Molecules* 2015;20:11524-34.
 78. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. *Oncogene* 2006;25:4798-811.
 79. Lavrik IN, Golks A, Krammer PH. Caspases: Pharmacological manipulation of cell death. *J Clin Invest* 2005;115:2665-72.
 80. Fan S, Xu H, Liu H, Hu Z, Xiao J, Liu H. Inhibition of cancer cell growth by Tangeretin flavone in drug-resistant MDA-MB-231 human breast carcinoma cells is facilitated via targeting cell apoptosis, cell cycle phase distribution, cell invasion and activation of numerous Caspases. *J BUON* 2019;24:1532-7.
 81. Granado-Serraw AB, Martin MA, Bravo L, Goya L, Ramos S. Quercetin induces apoptosis via caspase activation, regulation of BCL2 and inhibition of PI-3- kinase/AKT and ERK pathways in a human hepatoma cell line (HepG2). *Nutrition J* 2006;136:2715-21.
 82. Gregoraszcuk EL, Rak-Mardyla A, Rys J, Jakubowicz J, Urbański K. Effect of chemotherapeutic drugs on caspase-3 activity, as a key biomarker for apoptosis in ovarian tumor cell cultured as monolayer. A Pilot Study. *Iran J Pharm Res* 2015;14:1153-61.
 83. Vasekar M, Rizvi S, Liu X, Vrana KE, Zheng H. Novel immunotherapies for haematological malignancies. *Curr Mol Pharmacol* 2015;263:90-105.
 84. Hojjat-Farsangi M. Novel and emerging targeted-based cancer therapy agents and methods. *Tumour Biol* 2015;36:543-56.